• Maw: Governors impose masks. Trump opposes: preserving "a certain freedom"
  • Maw: vaccine within a year and a half, devastating coronavirus like Spanish
  • Coronavirus, US vaccine: testing started on 30,000 healthy volunteers

Share

July 28, 2020 "The October surprise of the vaccine" in the US "is possible". So the White House super virologist Anthony Fauci puts Donald Trump back into the game, with an assist that could catapult the president straight to his second term, despite the double-digit disadvantage in the polls against Democratic challenger Joe Biden, at 98 days from the Election Day. "We will get the victory over the virus by unleashing the American scientific genius," said the head of the White House triumphantly, after the announcement of the American Modern on the start of the final phase of the tests, followed closely by the turning point from that of Pfizer. The two companies received nearly two billion dollars in federal funds under Trump's "Operation Warp Speed" to win the vaccine race and secure reelection.

That the commander in chief was aiming for the big hit against Covid-19 is no secret. The novelty is the opening of the top expert on the vaccine available between October and November: the immunologist at the head of the National Institute of Allergy and Infectious Diseases. "I cannot guarantee success - Fauci points out - this is why clinical tests are carried out. But the premises are good".

 Currently there are about 25 vaccines in the clinic, that of human tests, according to data from the World Health Organization while infections in the States are over 4.2 million and deaths almost 150 thousand. In the race there are also the Chinese, the arms race against the coronavirus is a matter of geopolitical supremacy. Morgan Stanley estimates that the vaccine could guarantee those who find it first up to 30 billion in revenue per year in the initial immunization phase. In America "we made incredible progress," says Trump, who flew to Fujifilm Diosynth Biotechnologies headquarters in Morrisville, North Carolina yesterday, just hours after the news of the positivity of one of his closest collaborators, the national security advisor. Robert ÒBrien. The location of the visit was not chosen at random: the North Carolina biotech company was awarded a contract financed by the White House to develop the experimental Novavax vaccine, with the aim of bringing 300 million doses to the market by January of the next year.